In a report released on January 12, Eric Coldwell from Robert W. Baird maintained a Buy rating on Science 37 (SNCE – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $0.39.
Coldwell covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Cardinal Health, and Laboratory. According to TipRanks, Coldwell has an average return of 5.9% and a 54.47% success rate on recommended stocks.
Science 37 has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See Insiders’ Hot Stocks on TipRanks >>
SNCE market cap is currently $45.5M and has a P/E ratio of -0.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LifeSci Acquisition II Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.
Read More on SNCE:
- Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Science 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx Conference
- Science 37 and BEKHealth Collaborate to Expand Patient Access Via Community Providers
- Science 37 and Linical Announce Partnership to Enable Fully Decentralized and Hybrid Trials
